#ORPH Open Orphan Plc – £1.5m Contract renewal for Venn Life Sciences November 15, 2021 – Posted in: Blog, Open Orphan (ORPH)

(AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that Venn Life Sciences (“Venn”), a subsidiary of Open Orphan, has signed a contract renewal with a major global pharmaceutical client worth £1.5m over two years. The renewed contract will commence in January 2022, with the Venn team in Breda providing dedicated clinical pharmacokinetics (‘PK’) support to this leading global pharmaceutical client on an array of drug development programmes, to study…